Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 AlteredExpression group BEFREE Induction of diabetes by streptozotocin (STZ) increased the expression of PAR1, PAR3, and PAR4 in the aorta. 31759113 2020
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 AlteredExpression group BEFREE Abbreviations ADME absorption distribution metabolism excretion HTVS highthroughput virtual screening MD molecular dynamics MMGBSA molecular mechanics generalized bonn solvation accessible PDB protein data bank PPAR peroxisome proliferator-activated receptor RMSD Root mean square deviation RMSF Root mean square fluctuation SAR structural activity relationship SP simple precision T2DM TypeII diabetes mellitus XP Extra precision Communicated by Ramaswamy H. Sarma. 30767625 2020
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group BEFREE Inhibition of PXR should decrease adverse effects, improve therapeutic effectiveness, and advance clinical outcomes in patients with cancer, fatty liver, and diabetes. 30726709 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group BEFREE Induction of diabetes to PAR2-deficient (PAR2<sup>-/-</sup>) mice did not affect endothelial function and eNOS<sup>Ser1177</sup> phosphorylation in the aorta compared with non-diabetic PAR2<sup>-/-</sup> mice. 31371788 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group BEFREE Accordingly, insulin may impact the therapeutic effects of carboxylesterases substrate drugs and also inhibit expression of other genes targeted by PXR, thus inducing a wide range of potential drug-drug interactions (DDIs) during the treatment of diabetes. 31005591 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 GeneticVariation group BEFREE A Poisson regression model showed that histories of diabetes and hypertension were associated with a larger number of teeth with a PPD ≥5 mm (diabetes: prevalence rate ratio [PRR] 1.36, 95% confidence interval [CI] 1.00-1.85; hypertension: PRR 1.27, 95% CI 1.02-1.58) after adjusting for potential periodontal risk factors. 31217373 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group BEFREE Increasing evidences have suggested that PPAR, FXR, LXR ,PXR and CAR are involved in the development of diabetes and its complications through different mechanisms, including the regulation of glucose and lipid metabolism, insulin and inflammation response and related others. 29886826 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group BEFREE PXR has been shown to play a critical role in metabolic changes in obesity and diabetes; however, its distribution and function in the kidney are unknown. 29212764 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group BEFREE Dietary polyphenol EGCG could serve as a promising PXR/CAR activator and therapeutic intervention in diabetes. 30183039 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group BEFREE Notably, much experimental and clinical evidence show that PXR senses xenobiotics and triggers the detoxification response to prevent diseases such as diabetes, obesity, intestinal inflammatory diseases and liver fibrosis. 28534176 2017
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group BEFREE Chronic exposure to PXR agonists could potentially represent a risk factor for diabetes and metabolic syndrome. 27041449 2016
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 AlteredExpression group BEFREE Future studies are necessary to elucidate the effects of PAR1 upregulation in periodontally healthy sites and PAR2 downregulation in chronic periodontitis sites on the increased susceptibility and severity of periodontitis in diabetes. 26564991 2016
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group BEFREE Finally, these data identify PXR-humanized mice as a promising in vivo research model for studying obesity and diabetes in women. 24721462 2014
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.400 Biomarker group CTD_human CAR and PXR are involved in the development of certain diseases, including diabetes, metabolic syndrome and obesity. 20869355 2010
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Treatment with efavirenz-induced hypercholesterolemia and hepatic steatosis in mice but deficiency of hepatic PXR abolished these adverse effects. 30677459 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE In conclusion, our findings provide new insight into the molecular mechanisms of steatosis induction by triazole fungicides and identify PXR as a critical mediator of this process. 30989312 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Of note, PXR deficiency suppressed these changes and steatosis. 29123032 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE We have shown that PXR promotes chronic ethanol (EtOH)-induced steatosis. 29431616 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Cyproconazole dose-dependently activated RARα and PXR, two molecular initiating events in the steatosis AOP. 29995386 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Overall, our results uncover SLC13A5 as a novel target gene of PXR and may contribute to drug-induced steatosis and metabolic disorders in humans. 25628225 2015
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease CTD_human In summary, our data suggest that activation and knockdown of PXR in human hepatic cells promote de novo lipogenesis and steatosis by induction of the SREBP1 pathway and AKR1B10-mediated increase of ACC activity, respectively, thus providing mechanistic explanations for a putative dual role of PXR in the pathogenesis of steatohepatitis. 25182422 2015
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE In summary, our data suggest that activation and knockdown of PXR in human hepatic cells promote de novo lipogenesis and steatosis by induction of the SREBP1 pathway and AKR1B10-mediated increase of ACC activity, respectively, thus providing mechanistic explanations for a putative dual role of PXR in the pathogenesis of steatohepatitis. 25182422 2015
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice. 22790967 2012
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 GeneticVariation phenotype BEFREE Genetic polymorphisms in PXR and NF-κB1 influence susceptibility to anti-tuberculosis drug-induced liver injury. 31490979 2019
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.360 Biomarker phenotype BEFREE The canonical pathway comparison showed that VOAAF and DILI both worked on aryl hydrocarbon receptor (AHR), lipopolysaccharide (LPS)/interleukin 1 (IL-1) mediated inhibition of retinoid X receptor (RXR) function, pregnane X receptor (PXR)/RXR activation, xenobiotic metabolism, peroxisome proliferator-activated receptor (PPAR), hepatic cholestasis, farnesoid X receptor (FXR)/RXR activation, and glucocorticoid receptor. 29145837 2017